Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide and Lifestyle Modification in Obesity
NCT02911818Phase 4Completed
- Sponsor
- University of Pennsylvania
- Start
- Sep 2016
- Primary completion
- Nov 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liraglutide in obesity (5 arms), sponsored by University of Pennsylvania. Primary endpoints: Percent Change in Baseline Weight at 52 weeks and Extension Study Percent Change in Re-randomization Weight at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02911818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911818.